The Long & Short of It:
Optimizing Care in Short Bowel Syndrome

#3: Consult with the Expert

Certification period for this program has expired. No credit will be offered beyond the program dates noted on the bottom of this page.

This activity is jointly provided by Partners for Advancing Clinical Education (PACE) and Bonum CE in partnership with MondayNightIBD.

Supported by an educational grant from Takeda Pharmaceuticals U.S.A. Inc.

Program Overview

Short bowel syndrome (SBS) is a complex clinical condition that occurs from reduced or loss of intestinal absorption. SBS arises from a variety of causes, including surgical resection, congenital defects, or other diseases (such as cancer). This variation in etiology is one of the reasons why SBS is such a complex and heterogeneous disease. Symptoms of SBS vary according to the extent of bowel loss, but can include diarrhea and fatty stools, fatigue, weight loss, malnutrition, abdominal pain, and dehydration. To address the unique nutritional and clinical needs of patients with SBS, parenteral nutrition (PN) and intravenous (IV) fluid therapy have become a mainstay of treatment. However, PN itself is associated with complications. Management of patients with SBS has been further bolstered by the addition of two agents (teduglutide and somatropin). With multiple treatment modalities available, combined with the unique challenges associated with this condition, it is becoming increasingly understood that patients with SBS are best managed under a model of coordinated care.

This CME-certified, Twitter-based video Consult with the Expert, will focus on recognition and diagnosis of SBS, how to manage SBS locally, medical therapies for patients with SBS, and multidisciplinary team care of patients with SBS.

Faculty

Aline Charabaty, MD, AGAF, FACG
Assistant Clinical Director of the Division of Gastroenterology
Johns Hopkins School of Medicine
Clinical Director of IBD
Johns Hopkins - Sibley Memorial Hospital
Washington, DC

Valeria Cohran, MD, MS
Medical Director of Intestinal Rehabilitation and Transplant
Ann & Robert H Lurie Children’s Hospital of Chicago
Associate Professor of Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Simon Gabe, MD, MSc, BSc, MBBS, FRCP
Consultant Gastroenterologist
Chair, Intestinal Rehabilitation Unit
St Mark’s, the National Bowel Hospital
London, UK

Target Audience

This program is intended for gastroenterologists, surgeons, social workers, dietitians, pharmacists, nurses, nurse practitioners, physician associates/physician assistants, pediatricians, internists, psychologists, and feeding therapists involved in the care and management of patients with SBS.

Learning Objectives

After completing this activity series, learners should be better able to:

  • Interpret referral and treatment strategies to optimize a patient’s likelihood of achieving intestinal rehabilitation

  • Select pharmacologic options for treatment of pediatric patients with SBS

Disclosure of Relevant Financial Relationships

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

 
  • Aline Charabaty, MD, AGAF, FACG
    Consultant/Advisor/Speaker: AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer, Takeda

    Valeria Cohran, MD, MS
    Consultant/Advisor/Speaker: Abbott Nutrition, Nutricia, Takeda

    Simon Gabe, MD, MSc, BSc, MBBS, FRCP
    Consultant/Advisor/Speaker: Fresenius, Takeda
    Research Grants:
    Napa Therapeutics, Takeda, Zealand Pharma

  • PACE, Bonum CE staff and others involved with the planning, development, and review of the content for this activity have no relevant financial relationships to disclose.

Joint Accreditation Statement

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Bonum CE. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit & Fee Information

Certification period for this program has expired. No credit will be offered beyond the program dates noted on the bottom of this page.

In order to receive credit for this activity, the participant must read the front matter, achieve a passing score of 75% on the post-test, complete the evaluation and application for credit form.

There is no fee to participate in this activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

System Requirements

All Bonum CE digital activities require the following hardware/software to view and participate:

  • Internet connection (via PC or Mac desktop or laptop computer, tablet, mobile device, etc.)

  • PowerPoint and/or a PDF viewer may be required on some activities

We recommend a minimum of:

  • 128MB RAM

  • Processor speed of 500MHz or higher

  • 800x600 color monitor

  • Video or graphics card

  • Sound card and speakers

To actively participate in Bonum’s social media (SoMe)-based CME programs, learners will need to have an established account in good standing on that hosting SoMe site. Learners will need to be logged-in to the SoMe hosting platform.

For additional information about the accreditation of this activity, please visit https://www.partnersed.com

Release date: August 21, 2023
Expiration date: August 21, 2024
Estimated time to complete activity: 45 minutes